Nivolumab is also called OPDIVO. It is a targeted therapy drug currently used to treat melanoma, non-small cell lung cancer or kidney (renal cell) cancer. It may be used to treat other cancers as part of a clinical trial.
Nivolumab belongs to a group of cancer drugs known as monoclonal antibodies. It is also known as an immune checkpoint inhibitor. These drugs are sometimes called targeted therapies because they target specific proteins (receptors) on the surface of cells.
During treatment, you will see a cancer doctor or nurse. This is who we mean when we mention a doctor or nurse in this information.